Another ADC Buyout - Just not SPL, page-15

..... even with another ADC failure and all the ADC deals being done, Starpharma still don't seem to be able to sign an ADC license deal at this stage ?


I wonder if Gilead's failure will see them branch out ? I wonder if Gilead ever returned JF's call back in September 2020 in relation to the DEP® Remdesivir results she was touting to the market ?


https://www.healio.com/news/hematol...etastatic-lung-cancer-misses-primary-endpoint

Phase 3 study of Trodelvy for advanced lung cancer misses primary endpoint


Sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences) is a Trop-2-directed antibody-drug conjugate. The agent is approved for treatment of certain patients with breast cancer or urothelial cancer.